AbbVie has announced the acquisition of Gilgamesh Pharmaceuticals’ lead investigational drug – a next-generation psychedelic compound for moderate-to-severe major depressive disorder.

NICE unveils new type 2 diabetes guidance, promoting earlier access to advanced therapies such as SGLT-2 inhibitors and more.

Novartis is partnering with Atropos Health to develop AI models that accelerate rare disease diagnosis, starting with a rare blood disorder.

HonorHealth appoints Dr Nicholas Schork to lead AI-driven disease interception research, reflecting an industry shift towards prevention.

AstraZeneca and Viseven win the 2025 HBA ACE Awards for innovative workforce and community programmes shaping the future of healthcare.

AbbVie to invest $195m in manufacturing expansion as pharma rushes to boost domestic capacity ahead of expected drug import tariffs.

Bayer announces deal with Kumquat for a pancreatic cancer KRAS inhibitor, plus, promising mRNA vaccine research emerges from Phase 1 trial.

Ireland could become a global leader in FemTech innovation, but only if it acts now, claims a new report by Health Innovation Hub Ireland.